DHG Pharmaceutical (DHG) Stock Overview
Engages in the manufacture and sale of pharmaceutical products in Vietnam. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
DHG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
DHG Pharmaceutical Joint Stock Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₫99,600.00 |
| 52 Week High | ₫110,700.00 |
| 52 Week Low | ₫94,000.00 |
| Beta | 0.38 |
| 1 Month Change | -2.16% |
| 3 Month Change | -6.48% |
| 1 Year Change | 4.29% |
| 3 Year Change | 8.38% |
| 5 Year Change | 2.68% |
| Change since IPO | 142.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| DHG | VN Pharmaceuticals | VN Market | |
|---|---|---|---|
| 7D | -1.2% | -0.8% | 5.6% |
| 1Y | 4.3% | 8.9% | 42.9% |
Return vs Industry: DHG underperformed the VN Pharmaceuticals industry which returned 8.9% over the past year.
Return vs Market: DHG underperformed the VN Market which returned 42.9% over the past year.
Price Volatility
| DHG volatility | |
|---|---|
| DHG Average Weekly Movement | 1.9% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in VN Market | 8.2% |
| 10% least volatile stocks in VN Market | 3.1% |
Stable Share Price: DHG has not had significant price volatility in the past 3 months compared to the VN market.
Volatility Over Time: DHG's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | 2,819 | Toshifumi Kojima | www.dhgpharma.com.vn |
DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam. The company offers antibiotic, analgesic and antipyretic, respiratory, nutrition, musculoskeletal, gastrointestinal and hepatobiliary, nervous and ophthalmic, cardiovascular and diabetic, dermatology, and beauty care products. It also manufactures and trades in health food, dietary and consumer health supplements, and pharmaceuticals cosmetic products.
DHG Pharmaceutical Joint Stock Company Fundamentals Summary
| DHG fundamental statistics | |
|---|---|
| Market cap | ₫13.01t |
| Earnings (TTM) | ₫824.78b |
| Revenue (TTM) | ₫5.27t |
Is DHG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DHG income statement (TTM) | |
|---|---|
| Revenue | ₫5.27t |
| Cost of Revenue | ₫2.76t |
| Gross Profit | ₫2.51t |
| Other Expenses | ₫1.68t |
| Earnings | ₫824.78b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.31k |
| Gross Margin | 47.59% |
| Net Profit Margin | 15.66% |
| Debt/Equity Ratio | 0% |
How did DHG perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/15 09:48 |
| End of Day Share Price | 2026/04/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DHG Pharmaceutical Joint Stock Company is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hang Thi Vu | CGS International |
| Kien Giang | FPT Securities |
| Mi Thi Sony Nguyen | Maybank Research Pte. Ltd. |